Biosynex SA
Paris Stock Exchange ALBIO.PA
Biosynex SA Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -60.50 M
-
Biosynex SA Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -41.82 M, a -26.84% change year over year.
-
Biosynex SA Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -32.97 M, a -240.49% change year over year.
-
Biosynex SA Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -9.68 M.
| Date | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities | Dividends Paid | Capital Expenditure |
|---|
| CEO | Mr. Larry Abensur |
| IPO Date | March 28, 2011 |
| Location | France |
| Headquarters | 22 Boulevard Sébastien Brant |
| Employees | 515 |
| Sector | Health Care |
| Industries | |
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
Past 5 years
USD 26.07
StockViz Staff
January 15, 2025
Any question? Send us an email